Spinal Muscular Atrophy (SMA) Clinical Trials

Find Spinal Muscular Atrophy (SMA) Clinical Trials Near You

Advanced Multi-omics and -System Approaches to Identify Novel Biomarkers for SMA - Approcci Avanzati Multi-omici e Sistemici Per Identificare Nuovi Biomarcatori Per la SMA

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to motor neuron degeneration and progressive muscle atrophy. Despite recent advances in therapeutic options, the clinical management of SMA remains challenging due to the heterogeneity of disease progression and variability in treatment response. This study aims to identify and validate novel biomarkers to improve the diagnosis, prognosis, and therapeutic monitoring of patients with SMA through a multi-omics and translational research approach.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Genetically confirmed diagnosis of SMA, with homozygous deletion or mutation of the SMN1 gene, for symptomatic patients.

• Diagnosis of SMA through newborn screening, with genetic confirmation, for newborns.

• Ability of parents/legal guardians to provide informed consent for minor patients.

• Willingness to undergo the study procedures, including blood sampling and collection of biological specimens.

Locations
Other Locations
Italy
IRCCS Istituto Giannina Gaslini
RECRUITING
Genova
Fondazione Ca' Granda Ospedale Maggiore Policlinico
RECRUITING
Milan
Istituto di Bioscienze e Biorisorse IBBR
RECRUITING
Naples
Contact Information
Primary
Claudio Bruno, MD
claudiobruno@gaslini.org
+3901056362756
Time Frame
Start Date: 2025-02-05
Estimated Completion Date: 2026-12
Participants
Target number of participants: 200
Treatments
Patients with a genetic diagnosis of SMA types 1, 2, or 3
Newborns diagnosed with SMA through screening and with genetic confirmation.
Healthy age-matched controls with no personal or family history of neuromuscular diseases.
Sponsors
Leads: Istituto Giannina Gaslini
Collaborators: Piano Nazionale di Ripresa e Resilienza (PNRR)

This content was sourced from clinicaltrials.gov